Recursion Pharmaceuticals Inc is trading 8.8% down at $3.46 today as broad risk-off pressure impacts high-growth, tech-oriented sectors.
- The decline appears driven by a wider selloff in the growth and biotech space rather than new company-specific developments or rating changes.
- Analysts maintain a favorable Buy consensus, citing long-term optimism regarding the company's AI-driven drug discovery pipeline and Q1 2026 cost controls.